You are in: eMedicine Specialties > Pediatrics: General Medicine > Gastroenterology ConstipationArticle Last Updated: Jul 15, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Stephen Borowitz, MD, Professor of Pediatrics and Public Health Sciences, Department of Pediatrics, Division of Gastroenterology and Nutrition, University of Virginia Stephen Borowitz is a member of the following medical societies: American Academy of Pediatrics, American Gastroenterological Association, American Pediatric Society, North American Society for Pediatric Gastroenterology and Nutrition, and Society for Pediatric Research Editors: Chris A Liacouras, MD, Director of Pediatric Endoscopy, Department of Pediatrics, Division of Gastroenterology and Nutrition, Associate Professor, Children's Hospital of Philadelphia and University of Pennsylvania; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; Carmen Cuffari, MD, Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine; Steven M Schwarz, MD, FAAP, FACN, AGAF, Professor of Pediatrics, State University of New York, Downstate Medical Center College of Medicine; Distinguished Lecturer, New York Medical College, School of Public Health; Carmen Cuffari, MD, Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine Author and Editor Disclosure Synonyms and related keywords: constipation, acquired megacolon, functional constipation, functional megacolon, megacolon, stool hoarding, stool retention, stool withholding, Hirschsprung disease, defecation, fecal incontinence, abdominal mass, rectal fecal mass, painful defecation, acquired megacolon, encopresis, hypothyroidism, anal stenosis, imperforate anus, cow's milk allergy, celiac disease, fecal soiling, chronic diarrhea, anal fissures, fistula, hemorrhoids, obesity INTRODUCTIONBackgroundConcern about bowel function has been prevalent throughout history across many cultures. A normal bowel pattern is thought to be a sign of good health. Unfortunately, no uniform definition of childhood constipation is recognized. Moreover, health care providers have definitions of constipation that are very different than most parents' definitions. PathophysiologyMost children with constipation have no underlying medical condition. They are often labeled as having functional constipation or acquired megacolon. In most cases, childhood constipation develops when the child begins to associate pain with defecation. Once pain is associated with the passage of bowel movements, the child begins to withhold stools in an attempt to avoid discomfort. As stool withholding continues, the rectum gradually accommodates, and the normal urge to defecate gradually disappears. The infrequent passage of very large and hard stools reinforces the child's association of pain with defecation, resulting in worsening stool retention and progressively more abnormal defecation dynamics with anal sphincter spasm. Chronic rectal distension ultimately results in both loss of rectal sensitivity, and loss of the urge to defecate, which can lead to fecal incontinence (ie, encopresis). The differential diagnosis of childhood constipation can be extensive and may include Hirschsprung disease (ie, congenital megacolon), spinal or neuromuscular abnormalities, hypothyroidism, anal stenosis, imperforate anus with fistula, anterior displacement of the anus (this is a controversial diagnosis), allergy or sensitivity to cow's milk, and celiac disease. Fortunately, in most cases in which an underlying condition causes constipation, other stigmata of the disorder point to diagnosis. For example, constipation is rarely the only symptom of hypothyroidism. For practical purposes, in an otherwise healthy child, the differential diagnosis of chronic constipation is Hirschsprung disease and functional constipation (not Hirschsprung disease). Although this differentiation sometimes may be difficult, a number of clues in the history and physical examination are helpful (see Media file 1). FrequencyUnited StatesConstipation is extremely common among infants and young children. Issenman et al found that 16% of parents reported that their 2-year-old children had constipation.4 Loening-Baucke reported that the prevalence of constipation was 22.6% among 482 children aged 4-17 years.5 In a longitudinal study of children aged 9-11 years, Saps et al reported an 18% overall prevalence of constipation.6 InternationalYong and Beattie found that 34% of parents in the United Kingdom reported their children aged 4-7 years had at least intermittent difficulties with constipation.7 de Araujo Sant'Anna and Calcado found that 28% of Brazilian children aged 8-10 years were constipated.8 SexBefore puberty, constipation appears to be equally common among girls and boys. After puberty and into young adulthood, females are more likely to develop constipation. AgeConstipation occurs in all pediatric age groups from infancy to young adulthood. Typically, childhood constipation develops during 3 stages of childhood: in infants during weaning, in toddlers during toilet training, and in school-aged children. In several published reports, approximately half of childhood constipation occurs during the first year of life. CLINICALHistory
Physical
DIFFERENTIALSHirschsprung Disease Hypercalcemia Hypokalemia Hypothyroidism Imperforate Anus Neurofibromatosis
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Polyethylene glycol (MiraLax, GlycoLax) |
|---|---|
| Description | Polyethylene glycol (PEG) is a long chain of ethylene glycol molecules. The resulting molecule is extremely large, is very poorly absorbed, and functions as an osmotic laxative. These powders are tasteless and odorless and dissolve completely in nearly all liquids including water. These agents often can also be used as purgatives in preparation for colonoscopy. At very large dosages, PEG is occasionally difficult to take and its usage may be associated with nausea, bloating, abdominal cramps, and vomiting. |
| Adult Dose | Occasional constipation: 17 g mixed in 180 - 240 mL of fluid PO qd prn |
| Pediatric Dose | Mix 1 packet (17 g) in 240 mL to yield approximately 1 g per 14 mL; may store refrigerated for 48 h Disimpaction: 1-3 g (14-42 mL)/kg/d PO divided 2-4 doses Maintenance therapy in children 6 months to 15 years: ~0.5 g (7 mL)/kg/d PO qd or divided bid |
| Contraindications | Documented hypersensitivity; colitis, ileus, megacolon, bowel perforation, gastric retention, GI obstruction |
| Interactions | Do not administer PO medications within 1 h of initiation of therapy due to potential risk of reduced absorption |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Mixing the product in juice or other flavored fluids may make it more palatable; chilled product is more palatable; caution in ulcerative colitis and hot loop polypectomy |
| Drug Name | Magnesium hydroxide (Philips' Milk of Magnesia, Haley's MO) |
|---|---|
| Description | Magnesium is a divalent cation maximally absorbed in the distal small intestine. At low concentrations, magnesium appears to absorb by a saturable carrier-mediated process influenced by vitamin D. At higher concentrations, magnesium absorption appears to occur largely by diffusion and is quite inefficient. Increased serum magnesium levels may release cholecystokinin, which stimulates GI motility and secretion; this may explain why some children experience abdominal cramping. Mostly flavorless but has a thick, chalky texture. More palatable when mixed with a fluid (eg, milk, chocolate milk). |
| Adult Dose | 30-60 mL/d (as 400 mg/5 mL PO susp) PO qd or divided bid |
| Pediatric Dose | 1-3 mL/kg/d (as 400 mg/5 mL susp) PO qd or divided bid |
| Contraindications | Documented hypersensitivity; colostomy, ileostomy, fecal impaction, intestinal obstruction |
| Interactions | Decreases absorption of tetracyclines, digoxin, indomethacin, and iron salts |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Infants may be more susceptible to magnesium poisoning than older children and adults; overdosage can lead to hypermagnesemia, hypophosphatemia, and secondary hypocalcemia; administer magnesium-containing laxatives cautiously among patients with renal insufficiency because most of a magnesium load is excreted in the urine |
| Drug Name | Lactulose (Chronulac, Duphalac, Kristalose) |
|---|---|
| Description | Synthetic, nonabsorbable disaccharide available as a 70% solution. Generally very well tolerated and tastes sweet. Contains 10 g lactulose/15 mL of PO solution. |
| Adult Dose | 10-30 mL PO qd |
| Pediatric Dose | 1-3 mL/kg/d PO qd or divided bid |
| Contraindications | Documented hypersensitivity |
| Interactions | Neomycin may eliminate certain colonic bacteria and interfere with the desired degradation of lactulose, thus preventing colonic content acidification |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Exercise caution in patients with diabetes mellitus; at commonly used doses, often produces flatulence and occasional abdominal cramping |
| Drug Name | Sorbitol |
|---|---|
| Description | This alcohol of glucose is largely nonabsorbable. Available as a 70% solution. As with lactulose, generally well tolerated and tastes quite sweet. |
| Adult Dose | 30-150 mL PO qd prn |
| Pediatric Dose | 1-3 mL/kg/d PO qd or divided bid |
| Contraindications | Documented hypersensitivity; anuria |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | At commonly used doses, often produces flatulence and occasional abdominal cramping |
| Drug Name | Magnesium citrate |
|---|---|
| Description | Magnesium is a divalent cation maximally absorbed in the distal small intestine. At low concentrations, magnesium appears to absorb by a saturable carrier-mediated process influenced by vitamin D. At higher concentrations, magnesium absorption appears to occur largely by diffusion and is quite inefficient. Increased serum magnesium levels may release cholecystokinin, which stimulates GI motility and secretion; this may explain why some children experience abdominal cramping. |
| Adult Dose | 150-300 mL/d PO qd |
| Pediatric Dose | <6 years: 1-3 mL/kg/d PO qd 6-12 years: 100-150 mL/d PO qd >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; colostomy, ileostomy, fecal impaction, intestinal obstruction, diabetes mellitus, renal failure |
| Interactions | Decreases absorption and effects of tetracyclines, digoxin, indomethacin, and iron salts |
| Pregnancy | A - Fetal risk not revealed in controlled studies in humans |
| Precautions | Infants may be more susceptible to magnesium poisoning than older children and adults; overdosage can lead to hypermagnesemia, hypophosphatemia, and secondary hypocalcemia; administer magnesium-containing laxatives cautiously among patients with renal insufficiency, as most of a magnesium load is excreted in the urine; exercise caution in patients who are taking digoxin and lithium; product may be chilled to improve palatability |
| Drug Name | Sodium phosphate oral solution (Fleet Phospho-Soda) |
|---|---|
| Description | Phosphate is a divalent anion largely absorbed in the proximal small intestine. When administered as an enema, only small amounts are absorbed so the phosphate functions as an osmotic agent. Each 15 mL contains 7.2 g monobasic sodium phosphate monohydrate and 2.7 g dibasic sodium phosphate heptahydrate. |
| Adult Dose | 1 tablespoonful mixed with 8 oz water PO qd prn; may increase dose not to exceed 3 tablespoonfuls per day; drink at least 8 oz of extra fluid with each dose |
| Pediatric Dose | <5 years: Not recommended 5-9 years: Up to 1/2 tablespoon PO qd taken with eight ounces of fluid 10-11 years: Up to 1 tablespoon PO qd taken with eight ounces of fluid >12 years: Administer as in adults |
| Contraindications | Do not administer sodium phosphate to patients with renal insufficiency because severe and lethal episodes of hyperphosphatemia may develop with resultant hypocalcemia and tetany; fecal impaction |
| Interactions | Sucralfate or antacids that contain aluminum, calcium, or magnesium may bind phosphate in gut and decrease absorption (separate administration by at least 1 h); phosphate may also bind magnesium and reduce its absorption (separate administration by at least 1 h); anion exchange resins (eg, colestipol) may alter phosphate absorption; caution with other drugs that may lower seizure threshold (eg, antipsychotics); caution when coadministered with other drugs that prolong QT interval (eg, antipsychotics, macrolide antibiotics, class IA or class III antiarrhythmic agents); risk of acute phosphate nephropathy may increase with drugs that alter renal perfusion (eg, diuretics, ACE inhibitors, angiotensin II antagonists, NSAIDs) |
| Pregnancy | A - Fetal risk not revealed in controlled studies in humans |
| Precautions | Caution in congestive heart failure, and cirrhosis; electrolyte disturbances (eg, hypernatremia, hypokalemia, hyperphosphatemia, hypocalcemia) dehydration, metabolic acidosis, renal failure, tetany, and death have been attributed to prescribing >45 mL as bowel preparation for colonoscopy, surgery, or barium enema and/or prescribing it for people at medical risk |
These agents soften stools and decrease water absorption from the GI tract. They may also promote salt and water secretion by the colon.
| Drug Name | Mineral oil |
|---|---|
| Description | Nonabsorbable fat that softens stool and decreases water absorption, partly by its metabolism in the colon to hydroxy fatty acids. Largely tasteless. Has an oily consistency. More palatable if cold or mixed into a fluid (eg, orange juice). When taken in high doses, many children experience seepage of orange oil into their underwear, which can produce perianal pruritus. |
| Adult Dose | 15-45 mL PO qd prn |
| Pediatric Dose | <1 year: Not recommended >1 year: 1-3 mL/kg/d PO qd or divided bid |
| Contraindications | Documented hypersensitivity; do not administer to people with increased aspiration risk because aspiration of mineral oil can result in lipoid pneumonia |
| Interactions | Theoretically, mineral oil may interfere with absorption of fat-soluble vitamins; however, several long-term studies have not demonstrated any deleterious effects on vitamin levels; decreases effect of docusate sodium and may decrease absorption of warfarin, or PO contraceptives |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Do not administer with food or meals since may cause aspiration leading to lipid pneumonitis |
These agents increase peristaltic activity in the GI tract. Most of these agents also stimulate salt and water secretion in the colon.
| Drug Name | Senna (Ex-Lax, Senokot, Fletcher's Castoria, Aloe Vera) |
|---|---|
| Description | Sennosides are plant alkaloids that stimulate colonic salt and water secretion and promote colonic motility. At higher doses, these agents often produce abdominal cramping. Long-term use in animals has not been associated with any evidence of cathartic colon, tachyphylaxis, or secondary hyperaldosteronism. |
| Adult Dose | 10-15 mL PO qhs prn |
| Pediatric Dose | <2 years: Not recommended 2-5 years: 2.5-5 mL/dose (8.8 mg of sennosides/5 mL) PO qd/bid >5 years: 5-10 mL/dose (8.8 mg of sennosides/5 mL) PO qd/bid |
| Contraindications | Documented hypersensitivity; bowel obstruction, fecal impaction |
| Interactions | Decreases effects of anticoagulants |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Chronic use of sennosides can be associated with melanosis coli (brown pigment accumulation in the colonic mucosa); this finding does not appear to have any pathological significance and resolves within several months of discontinuing the laxative |
| Drug Name | Bisacodyl (Dulcolax) |
|---|---|
| Description | Colorless and odorless compound that is very poorly absorbed. Can be administered PO or rectally. Bisacodyl increases colonic peristalsis and stimulates salt and water secretion. |
| Adult Dose | 5-15 mg PO as single dose 10 mg PR as single dose |
| Pediatric Dose | <2 years: Not recommended >2 years: 0.5-1 of a 10-mg suppository/dose PR or one third of the 5-mg tab/dose PO |
| Contraindications | Documented hypersensitivity; intestinal obstruction |
| Interactions | Decreases effects of warfarin and antacids |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | At higher doses, these agents often produce abdominal cramping |
These agents allow incorporation of water and fat into stool, causing stool to soften.
| Drug Name | Docusate sodium (Colace, DC 240 Softgels, Diocto, Surfak) |
|---|---|
| Description | Used to avoid straining during defecation. Allows incorporation of water and fat into stool causing stool to soften. |
| Adult Dose | 50-400 mg/d PO qd or divided qid |
| Pediatric Dose | 3-6 years: 20-60 mg/d PO qd or divided qid 6-12 years: 40-150 mg/d PO qd or divided qid >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; nausea, vomiting, acute abdominal pain |
| Interactions | Decreases effects of warfarin and increases effects of phenolphthalein |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Prolonged use of medication may result in electrolyte imbalance |
Emollient stool softeners cause stool to soften. Most of these agents also promote salt and water secretion by the colon. Stimulants increase peristaltic activity in the GI tract. Most of these agents also promote salt and water secretion by the colon.
| Drug Name | Docusate sodium and casanthranol combination (Peri-Colace, Diocto C, Silace-C) |
|---|---|
| Description | Docusate sodium allows incorporation of water and fat into stool causing stool to soften. Casanthranol is an anthraquinone stimulant hydrolyzed by colonic bacteria into active compound. Usually produce action 8-12 h after administration. |
| Adult Dose | 1-4 cap or tab PO hs Alternatively, 5-60 mL PO hs if syrup or emulsion administered |
| Pediatric Dose | <6 years: Not recommended >6 years: 1-2 cap or tab PO hs; alternatively, 5-15 mL PO hs if syrup or emulsion administered |
| Contraindications | Documented hypersensitivity; nausea, vomiting, GI bleeding, appendicitis, GI bleeding, congestive heart failure, fecal impaction, appendicitis, nausea, vomiting, acute abdominal pain |
| Interactions | Decreases effects of warfarin and increases effects of phenolphthalein |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Excessive use may lead to electrolyte imbalance, osteomalacia, steatorrhea, cathartic colon |
These agents produce osmotic effect in colon that results in distention and promotes peristalsis.
| Drug Name | Sodium phosphate enema (Fleet enema) |
|---|---|
| Description | Phosphate is a divalent anion largely absorbed in the proximal small intestine. When administered as an enema, only small amounts are absorbed so the phosphate functions as an osmotic agent drawing water into intestinal lumen increasing intraluminal and hydrostatic pressure. May also decrease water and electrolyte absorption. |
| Adult Dose | 1 adult enema (4.5 fl.oz) PR prn |
| Pediatric Dose | <2 years: Do not use 2-5 years: 1 pediatric enema (2.25 fl.oz) PR once or twice daily prn >5 years: 1 adult enema (4.5 fl. oz) PR once or twice daily prn |
| Contraindications | Documented hypersensitivity; hypernatremia, hyperphosphatemia, renal failure, hypocalcemia, and fecal impaction |
| Interactions | Do not administer aluminum, magnesium antacids, or sucralfate |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in congestive heart failure, and cirrhosis; electrolyte disturbances (eg, hypernatremia, hypokalemia, hyperphosphatemia, hypocalcemia) dehydration, metabolic acidosis, renal failure, tetany, and death have been attributed to prescribing >45 mL as bowel preparation for colonoscopy, surgery, or barium enema and/or prescribing it for people at medical risk |
| Media file 1: Differentiating functional constipation and Hirschsprung disease. | |
![]() | View Full Size Image | Media type: Graph |
| Media file 2: Unprepared single contrast barium enema demonstrating a transition zone consistent with Hirschsprung disease. | |
![]() | View Full Size Image | Media type: Radiograph |
| Media file 3: Plain abdominal radiograph that demonstrates stool throughout the colon. | |
![]() | View Full Size Image | Media type: Radiograph |
| Media file 4: Normal anorectal manometry that demonstrates relaxation of the internal anal sphincter in response to rectal distension. | |
![]() | View Full Size Image | Media type: Graph |
| Media file 5: Common withholding behaviors in young children. | |
![]() | View Full Size Image | Media type: Graph |
Article Last Updated: Jul 15, 2008